Last reviewed · How we verify
Any biologic treatment for psoriasis
Tildrakizumab blocks the interaction between interleukin-23 (IL-23) and its receptor, reducing inflammation in the body.
Tildrakizumab blocks the interaction between interleukin-23 (IL-23) and its receptor, reducing inflammation in the body. Used for Moderate to severe plaque psoriasis, Moderate to severe scalp psoriasis.
At a glance
| Generic name | Any biologic treatment for psoriasis |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | IL-23 inhibitor |
| Target | IL-23R |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
IL-23 is a cytokine that plays a key role in the development of psoriasis. By blocking the IL-23 receptor, tildrakizumab reduces the production of pro-inflammatory molecules, leading to decreased inflammation and improved symptoms in patients with psoriasis.
Approved indications
- Moderate to severe plaque psoriasis
- Moderate to severe scalp psoriasis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Injection site reaction
- Fatigue
Key clinical trials
- Psoriasis Longitudinal Assessment and Registry
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
- Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis (PHASE4)
- Brain Changes in Psoriasis After Secukinumab Treatment (PHASE4)
- A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
- Association Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of Patients With pSOriasis
- Evaluation of the Role of Inflammatory and Structural Ultrasound Abnormalities by Explaining the Perspective of Patients With Psoriatic Arthritis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |